AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05460169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation
Description: The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
Study NCT05201495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Description: Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
Study NCT06527937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DESF
Description: DESF administered in the sublingual space.
Study NCT06527937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Injection
Description: Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
Study NCT06399692 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting (CABG)
Description: Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
Study NCT06399692 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
Study NCT06122662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: Proprietary formulation of sodium phenylbutyrate and taurursodiol
Study NCT06528977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western Diet
Description: Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
Study NCT06042998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic radical gastrectomy
Description: Laparoscopic gastrectomy
Study NCT06042998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic radical gastrectomy
Description: Laparoscopic gastrectomy
Study NCT05328440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine
Study NCT05328440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isethionate Tablets
Description: 400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle
Study NCT05328440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.
Study NCT05328440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
Study NCT06122662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Comparator
Study NCT05053308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: IV PCA(fentanyl) Fentanyl bolus = MME \* 15%
Study NCT05053308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Tablet
Description: subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
Study NCT06088901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Patch
Description: 2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
Study NCT06449547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
Study NCT05531825 — intervention group
Intervention type: DEVICE
Intervention: A device for detecting arteriovenous fistula vascular function
Description: An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
Study NCT05320302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-Lu AF88370
Description: PET ligand in a single intravenous bolus injection
Study NCT05242523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot scent
Description: The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
Study NCT05242523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural wood scent
Description: Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
Study NCT05881278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Description: Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Study NCT05529940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
Study NCT05529940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
Study NCT06402084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasound
Description: abdominal ultrasound and lipid profile will be done
Study NCT06497075 — intervention group
Intervention type: DRUG
Intervention: Albendazole 400mg
Description: Single oral dose of Albendazole 400mg tablet
Study NCT06497075 — intervention group
Intervention type: DRUG
Intervention: Ivermectin 3 MG
Description: Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or > 158 cm: 4 tablets)
Study NCT04968379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Intravenous
Study NCT04878887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IP-DRA vs IP- PRA
Description: Catetherization approach in plane : distal radial artery VS proximal radial artery
Study NCT05777018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional recruitment maneuvers
Description: The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings
Study NCT05777018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided recruitment maneuvers
Description: * Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure.
Study NCT05561374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose OKN-007, BID
Description: Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
Study NCT05561374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose OKN-007, TID
Description: Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
Study NCT05561374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid-dose OKN-007, TID
Description: Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
Study NCT05561374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose OKN-007, TID
Description: Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
Study NCT06094192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition transcranial electrical current stimulation
Description: Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
Study NCT05398926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero cell), Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT06094192 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High definition transcranial electrical current stimulation
Description: Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
Study NCT05364606 — intervention group
Intervention type: DEVICE
Intervention: Patient Specific Talus Spacer
Description: Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
Study NCT06146660 — intervention group
Intervention type: DRUG
Intervention: Mavacamten
Description: According to approved product label
Study NCT05761392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precise management
Description: The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
Study NCT06640608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT - Internet Based Cognitive Behavioral Therapy
Description: The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
Study NCT05753631 — intervention group
Intervention type: PROCEDURE
Intervention: non surgical periodontal treatment
Description: scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated.
Study NCT05659056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib, trastuzumab, paclitaxel-albumin
Description: pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
Study NCT04824729 — intervention group
Intervention type: PROCEDURE
Intervention: Lower limb revascularization
Description: French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
Study NCT04824729 — intervention group
Intervention type: PROCEDURE
Intervention: Lower limb revascularization
Description: French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
Study NCT04581759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC device (IPC-906X)
Description: Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
Study NCT04581759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foundational treatment
Description: foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
Study NCT04581759 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: foundational treatment
Description: foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
Study NCT04464603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterFACE (mHealth tool)
Description: Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support.
Study NCT04464603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional methods
Description: Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool.
Study NCT05973331 — intervention group
Intervention type: OTHER
Intervention: Pancreatic Cancer Risk Model (PRISM)
Description: A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
Study NCT05245955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessments of the hand sensory function with the ReHapticKnob
Description: During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
Study NCT04149301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3D gait analysis
Description: Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
Study NCT04149301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
Study NCT04554498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Description: 1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands).
Study NCT04554498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Description: 1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands).
Study NCT06227754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI group
Description: The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
Study NCT06227754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided PCI group
Description: \[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) >80% of the average reference lumen area OR >4.5 mm2~   ② In LM lesion: MSA>7 mm2 for distal LM and >8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as >60° of the circumference of the vessel at site of dissection and/or >2 mm in length of dissection flap)
Study NCT05745636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli, mustard, vitamin C
Description: 2 capsules per day for 4 weeks
Study NCT05745636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules per day for 4 weeks.
Study NCT05385900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combination with anlotinib and chemotherapy
Description: Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time